A. Hattersley

First name
A.
Middle name
T.
Last name
Hattersley
Farmer, A. J., Rodgers, L. R., Lonergan, M., Shields, B., Weedon, M. N., Donnelly, L., et al. (2016). Adherence to Oral Glucose-Lowering Therapies and Associations With 1-Year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database. Diabetes Care. http://doi.org/10.2337/dc15-1194
Rodgers, L. R., Weedon, M. N., Henley, W. E., Hattersley, A. T., & Shields, B. M. (2017). Cohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes. BMJ Open. http://doi.org/10.1136/bmjopen-2017-017989
Dennis, J. M., Henley, W. E., Weedon, M. N., Lonergan, M., Rodgers, L. R., Jones, A. G., et al. (2018). Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care. http://doi.org/10.2337/dc18-0344
Curtis, H. J., Dennis, J. M., Shields, B. M., Walker, A. J., Bacon, S., Hattersley, A. T., et al. (2018). Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes Obes Metab. http://doi.org/10.1111/dom.13346
Dennis, J. M., Shields, B. M., Hill, A. V., Knight, B. A., McDonald, T. J., Rodgers, L. R., et al. (2018). Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care. http://doi.org/10.2337/dc17-1827
Dennis, J. M., Henley, W. E., McGovern, A. P., Farmer, A. J., Sattar, N., Holman, R. R., et al. (2019). Time trends in prescribing of type 2 diabetes drugs, glycemic response and risk factors: a retrospective analysis of primary care data, 2010-2017. Diabetes Obes Metab. http://doi.org/10.1111/dom.13687
McGovern, A. P., Dennis, J. M., Shields, B. M., Hattersley, A. T., Pearson, E. R., & Jones, A. G. (2019). What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study. BMC Med. http://doi.org/10.1186/s12916-019-1307-8
Shields, B. M., Hattersley, A. T., & Farmer, A. J. (2019). Identifying routine clinical predictors of non-adherence to second line therapies in Type 2 diabetes: a retrospective cohort analysis in a large primary care database. Diabetes Obes Metab. http://doi.org/10.1111/dom.13865
McGovern, A. P., Hogg, M., Shields, B. M., Sattar, N. A., Holman, R. R., Pearson, E. R., et al. (2020). Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2020-001238
Rodgers, L. R., Dennis, J. M., Shields, B. M., Mounce, L., Fisher, I., Hattersley, A. T., & Henley, W. E. (2020). Prior event rate ratio adjustment produced estimates consistent with randomised trial: a diabetes case study. J Clin Epidemiol. http://doi.org/10.1016/j.jclinepi.2020.03.007